Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
Noosa News18 hours agoTallest tower outside CBD approved for construction at 205 metres
-
Noosa News6 hours agoJessica Alba spotted filming spy thriller on the Gold Coast as cameras roll under iconic bridge
-
Noosa News23 hours agoTrucking company penalised for refusing to pay unfairly sacked worker
-
Noosa News19 hours agoFarmgate Backpackers leads with integrity amid industry challenges